Experts believe CMS' price transparency rule is flawed in its design because the highly complex billing data it is asking hospitals to post is too confusing for consumers to understand. The complicated structure of the healthcare system — from care variance to deductibles to billing codes — means that producing an accurate price estimate is virtually impossible. To improve compliance, hospitals will need health tech companies to step in.
Webinar Date: July 20, 2022 Time: 2:00pm ET / 11:00am PT
This webinar discusses how a human-computer team takes advantage of the clinical expertise and complex problem-solving ability of humans for the more challenging clinical registry fields and the speed and accuracy of AI technology for the more straightforward fields. The result is more accurate, timely data for clinical registries and internal patient care projects.
Other topics discussed:
The strengths and limitations of AI
Why a human+computer approach to data mining yields the best results
How AI methods such as machine learning and natural language processing can standardize clinical registry data
How to make clinical registry data available in real time across hospital systems for patient care, quality initiatives, and other internal projects
Don't miss out on this valuable opportunity to meet and discuss the latest trends and opportunities. Don't miss your chance to save with the Super Early Bird Rate.
The new FDA approval for Breyanzi moves the Bristol Myers Squibb cancer cell therapy into an earlier line of treatment for an aggressive type of blood cancer. The decision also gives the pharmaceutical giant access to an additional pool of patients untapped by a rival cell therapy from Gilead Sciences.
Startups should co-develop products with healthcare providers and figure out how to plant themselves into hospitals and clinics' operating models. This will allow them to create effective technology, according to the healthcare executives speaking at a Monday panel on alleviating healthcare inefficiencies through innovation.
Ipsen is paying $247 million to acquire Epizyme, a cancer drug developer with one FDA-approved product: follicular lymphoma therapy Tazverik. The drug is a modest seller now, but more cash could be paid out if the small molecule hits sales targets in coming years.
A pediatric health system enlisting mixed reality and 3D printing technology illustrates how clinical collaboration and patient education can improve patient outcomes for complex procedures.
Replace the tedious manual resume screening process! Learn how AI frameworks and technology are streamlining the recruiter/candidate experience, resulting in healthcare industries hiring skilled and knowledgeable personnel quickly and effectively.
No comments